For conventional antibody detection, our primary considerations are specificity and affinity. However, in the case of functional antibodies, in addition to these two metrics, one must also consider the involvement of antibodies in humoral immunity and innate immune activity.

（Delidakis G, et al. Annu Rev Biomed Eng. 2022）

Specifically, the IgG-Fc domain participates in various mechanisms (ADCC, ADCP and CDC) leading to targeted cell death through interaction with Fc receptors and the complement factor C1q.

（Delidakis G, et al. Annu Rev Biomed Eng. 2022）

For applications in tumor immunology, antibody-mediated cell killing is essential. Various techniques have been developed to enhance the so-called Fc effector functions. However, when therapeutic antibodies simply act as blockers to prevent ligand-receptor interactions, Fc effector functions are unnecessary, as they may exhibit high cytotoxicity, harming normal cells.

（Vonderheide RH, et al. Clin Cancer Res. 2013）

Based on the antibody engineering and modification platform, Mabnus Biotech, through extensive screening assessments including Fc receptor binding (SPR) and C1q binding (ELISA), customizes chimeric antibodies with different subtypes and antibody framework differences tailored to specific antibody application requirements in academic research or industry. Simultaneously, the core amino acid sites on the Fc can be mutated to create functionally differentiated antibodies.